Greatbatch to Buy Enpath for $102 Million

Greatbatch, of Clarence, NY, said today that it would acquire Minneapolis-based Enpath Medical for $102 million. The purchase, which includes assumption of debt (about $5.5 million worth, according to the Associate Press), gives Greatbatch an increased presence in the cardiac rhythm management and neurostimulation markets.    

Enpath’s main product lines include the following: Venous vessel introducers and valved introducers that enable physicians to create a conduit through which they can insert infusion catheters, implantable ports and pacemaker leads into a blood vessel; advanced delivery catheters that can be manipulated so that doctors can access parts of the patient’s anatomy that cannot be reached by traditional introducers; and implantable stimulation leads, adaptors and delivery systems for the cardiac and neuromodulation markets.

Banc of America Securities and Greene Holcomb & Fisher, respectively, are acting as lead advisors to Greatbatch and Enpath.

The comments are closed.